Although life for the general public is (slowly) starting to edge back towards normality, healthcare providers are still on a heightened state of alert.
Life science companies must evolve and find new ways of working that erase the lines between industries and sub-sectors if they are to adapt to the digitalised world.
The pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for patients, healthcare professionals and society.
COVID-19 might have forced pharma to finally fully embrace digital comms, but it’s been a steep learning curve and expertise varies across the industry.
Sandoz’s Pierre Bourdage looks at the unexpected secondary impacts of COVID-19 on countries and healthcare systems, and asks how pharma can help improve sustainability to tackle them.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.